Plasma Tissue Factor Pathway Inhibitor Levels as a Marker for Postoperative Bleeding After Enoxaparin Use in Deep Vein Thrombosis Prophylaxis in Orthopedics and General Surgery
Free accessOtherFirst published online January, 2001
Plasma Tissue Factor Pathway Inhibitor Levels as a Marker for Postoperative Bleeding After Enoxaparin Use in Deep Vein Thrombosis Prophylaxis in Orthopedics and General Surgery
Low-molecular-weight heparins (LMWH) are widely used as antithrombotic prophylactic pharmaceutical agents in orthopedic and general surgery. Their antithrombotic characteristics are expressed by plasma mediators such as anti-Xa, anti-Ila, and increased release of tissue factor pathway inhibitor (TFPI) from vascular endothelium. The purpose of this clinical research is to study the relation between plasma levels of these mediators and postoperative bleeding.
Forty-one consecutive patients undergoing hip or knee arthroplasty (n = 36) and colectomy (n = 5) received the standard enoxaparin (a LMWH) dose preoperatively (general surgery) or immediately postoperatively (orthopedic surgery). Major bleeding was defined as a postoperative drop of ≥ 5 g/dL) of hemoglobin. The authors observed that there was a linear relationship between an increase in free/total TFPI ratio levels and postoperative bleeding. When that ratio increased by >60%, the hemoglobin dropped to >5 g/dL (n = 13).
This relationship between free/total TFPI ratio increase and postoperative bleeding was statistically significant (P < 0.001). Those who did not bleed (hemoglobin drop was less than 5 g/dL) (n = 28) had a ratio increase (if any) of less than 50%. However, the authors did not observe any statistical relationship between anti-Xa, anti-IIa, or prothrombin time and postoperative bleeding in patients receiving LMWH for deep vein thrombosis prophylaxis in orthopedic and general surgery patients. The authors recommend a pre- and postoperative ratio level measurement whenever major bleeding is anticipated, as adjustments of LMWH dose or frequency might be necessary.
Hoppensteadt DA, Walennga JM, Fasanella A., Jeske J., Fareed J.Antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res1995;77(2) -175.
2.
Holst J., Lindblad B., Mattiasson SE, Stjemquist U., Ezban M., Ostergaard PB, Hedner U.Experimental haemorrhagic effect of two-domain non-glycosylated tissue factor pathway inhibitor compared to low molecular weight heparin. Thromb Haemost1996;74(4): 585.
3.
Hansen JB, Sandset PM, Huseby KR, Huseby NE, Beendz B. Ostergaard P, Nordoy A.Differential effect of unfractionated heparin and low molecular weight heparin on intravenous tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. Br J Haematol1998 ;101(4):638.
4.
Bara L., Planes A., Samama M.Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, witi-Ilaa activities, and D-dimer plasma levels in pationts receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol1999;104(2):230.
5.
Horlocker TT , Wedel DJNeuraxial block and low-molecular weight heparin: balancing perioperative analgesia and thromboprophylaxis. Reg Anesth Pain Med1998;23(Suppl 2):164.
6.
Eriksson BI, Katebo P., Anthmyr BA, Wadenvik H., Tengbor L., Risberg B.Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. J Bone Joint Surg1991;73-A(4):484.
7.
Samama MM, Bara L., Gerotziafas GTMechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs). Haemostasis1994:24:105.
8.
Bara L., Bloch MF, Zitoun D., et al. Comparative effects of Enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation. and release of tissue factor pathway inhibitor. Thromb Res1993;69(5): 443.
9.
Kijowski R., Hoppensteadt D., walenga J., Borris L., Lassen MR, Fareed J.Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxsis in patients treated with low molecular weight heparin. Thromb Res1994;74(1):53.
Ariens Ras, Alberio G., Moia M., Mannucci PMLow levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb Haemost1999 ;81(2):203.
12.
Holst J., Lindblad B., Matthiasson SE, Stjernquist U., Ezban M., Ostergaard PB, Hedner U.Experimental haemorrhagic effect of two domain non-glycosylated tissue factor pathway inhibitor compared to low molecular weight heparin. Thromb Haemost1996;75 (4):585.
13.
Spiro TE, Fitzgerald RH, Trowbridge AA, et al. for the Enoxaparin Clinical Trial Group.Enoxaparin, a low molecular weight heparin and warfarin for the prevention of venous thromboembolic disease after elective knee replacement surgery. Blood1994;84(Suppl): 246a.
14.
Colwell CW, Haas SB, Lotke PA, Paiement GD, Sculco TPThromboembolic disease in orthopaedic surgery. American Academy of Orthopaedic Surgeons 65th Annual Meeting. Instructional Course Lectures Handout Cover, Course Number: 132.
15.
Bierbaum BE , Callaghan JC, Galante JO, et al. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg1999;81-A:2.
16.
Kessler CM, Esparraguera IM, Jacobs HM, et al. Monitoring the anticoagulanat effects of a low molecular weight heparin preparation. Coagulation Transfusion Med1995;103(5):642.
17.
Abbate R., Gori AM, Farsi A., Attanasio M., Pepe G.Monitoring of low-molecular-weight heparins in cardiovascular disease. Am J Cardiol1998;82(5B):33L.
18.
Hamulyak K. , Lensing Awa, Van der Meer J., Smid WM, Van Ooy A., Hoek JASubcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in effective hip and knee replacement?Thromb Haemost1994 ;74(6): 1428.
19.
Shaieb MD, Watson BN, Atkinson REBleeding complications with enoxaparin for deep venous thrombosis prophylaxis . J Ar— throplasty1999;14(4):432.
20.
Spiro TE, Colwell CWEfficacy and safety of enoxaparin for the prevention of deep vein thrombosis after hip replacement surgery. Orthop Rev1994;XXIII(3A):47.
21.
Turpie Agg, Levine MN, Hirsh J., et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. Heparin Deep-Vein Thromb1986 ;315(15):925.
22.
Planes A., Vochelle N., Fagola M., Feret J., Bellaud M.Prevention of deep vein thrombosis after total hip replacement. J Bone Joint Surg1991;73-B(3):418.
23.
Erikson BI, Kalebo P., Anthmyr BA, Wadenvik H., Tengbom L., Risberg B.Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. J Bone Joint Surg1991;73-A(4):484.
24.
Francis CW, Pellegrini VD, Totterman S., et al. Prevention of deep-vein thrombosis after total hip replacement . J Bone Joint Surg1997;79-A(9):1365.
25.
Kakkar VV, Corrisan T., Spindler J., Fossard DP, Flut PTEfficacy of low doses of heparin in prevention of deep vein thrombosis after major surgery: a double-blind randomized study. Lancet1972;1: 101.
26.
Mcnally MA, Cooke EA.Harding ML , Mollan RA.Attitudes to, and utilization of, low molecular weight heparins in joint replacement surgery . J R Coll Surg Edinb1997;42(6):407.
27.
Fareed J., et al. Tissue factor antigen levels in various biological fluids. Blood Coagulation Fibrinolysis1995;6:1.
28.
Bang CJ, Berstad A., Tatstad I.Haemorrhagic effects of unfractionated and two low molecular weight heparins, enoxaparin and fragmin, in rats. Haemostasis1901;21(1):30.
29.
Eriksson BISoderberg K., Widlund L., Wandeli B.Tengborn L., Risberg B.A comparison study of three low-molecular weight hephrins (LMWH) and unfractionated heparin (UH) in healthy volunteers . Thromb Haemost1995:73(3):398.
30.
Planes A., Vochelle N., Fagola M., Bellaud M.Comparison of two low-molecular-weight heparin for the prevention of postoperative venous thromboembotism after elective hip surgery. Reviparin Study Group. Blood Coagulation Fibrinolysis1998;9(6):499.
31.
Barsotti J. , Gruel Y., Rosset P., et al. Comparative double-blind study of two dosage regimens of low-molecular weight heparin in elderly patients with a fracture of the neck of the femur. J Orthop Trauma1990;4(4):371.
32.
Gjengedal E. , Uppheim G.Clexane (enoxaparin) or Fragmin (dalteparin) for thrombolytic prevention in hip replacement surgery?Tidsskr Nor Laegeforen1996; 116(15):1782.
33.
Hamamoto T. , Kisiel W.The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor. Blood Coagulation Fibrinolysis1996;7(4):470.
34.
Bick RL, et al. Heparin realistic tissue factor pathway inhibitor during interventional cardiovascular procedures. Blood1994;84: 81.
35.
Fareed J., et al. Platelet factor 4 and antithrombin are not the sole determinants of the heparinzation response. Circulation1994;90; 180.
36.
Ostergaard P., Nordfang O., Peterson LC, Valentin S., Kristensen H.Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins?Haemostasis1993;23(Suppl 1):107.
37.
Hoppensteadt DA, Jeske W., Fareed J., Bermes EWThe role of tissue factor pathway inhibitor in the medication of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagulation Fibrinolysis1995 ;6(Suppl 6):S57.
38.
Jeske W., Hoppensteadt D., Callas D., Koza MJ, Fareed J.Pharmacological profiling of recombinant tissue factor pathway inhibitor . Thromb Hemost1996;22(2):213.
39.
Hamamoto T. , Kisiel W.The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor. Blood Coagulation Fibrinolysis1996;7(4):470.
40.
Hamamoto T. , Kisiel W.Full-length human tissue factor pathway inhibitor inhibits human activated protein C in the presence of heparin . Thromb Res1995;80(4):291.
41.
Gouin-Thibault I., Dewar L., Craven S., Kulczcky M.Wun TC, Ofosu FAProbable regulation of factor VIIa-tissue factor and prothrombinase by factor Xa-TFPI and TFPI in vivo. Br J Haematol1996;95(4):738.
42.
Kaiser B., Hoppensteadt DA, Jeske W., Wun TC, Fareed J.Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro-modulatory action of glycosaminoglycans. Thromb Res1994 ; 75(6):609.
43.
van't Veer C., Mann KGRegulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. J Biol Chem1997;272(7):4367.
44.
Hoppensteadt DA, Jeske W., Fareed J., Bermes EW Jr.The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagulation Fibrinolysis1995 ;6(Suppl 1):S57.
45.
Kijowski R. , Hoppensteadt D., Walenga J., Borris L., Lassen MR, Fareed J.Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxis in patients treated with low molecular weight heparin. Thromb Res1994;74(1):53.
